Cornerstone BioPharma’s efforts to build a nationwide sales force continues to progress with 25 more sales representatives coming on board, the company said Tuesday.

The new hires join 50 sales reps who were hired in April.

Cornerstone, which is focused on drugs to treat pain, respiratory problems and to prevent infections, plans to release several products this year. The company recently won FDA approval for Balacet 325, a treatment for mild to moderate pain in patients ages 18 and older.